Inactive Instrument

Bruker Cellular Analysis, Inc.

Equities

BLI

US0843101017

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PhenomeX Inc Announces Board Changes CI
PhenomeX Inc. has Changed its Name to Bruker Cellular Analysis, Inc CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from NASDAQ Composite Index CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from S&P TMI Index CI
Bruker Corporation completed the acquisition of PhenomeX Inc.. CI
Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform CI
PhenomeX Inc. Announces the Release of SpotLight? Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from S&P Global BMI Index CI
Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark? Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics CI
North American Morning Briefing : Nasdaq Futures -2- DJ
TD Cowen Downgrades PhenomeX to Market Perform From Outperform, Price Target is $1 MT
North American Morning Briefing : Nvidia Results -2- DJ
Berenberg Downgrades PhenomeX to Hold From Buy, Adjusts Price Target to $1 From $8 MT
North American Morning Briefing : Focus Shifts to -2- DJ
Morgan Stanley Upgrades PhenomeX to Equalweight From Underweight, Adjusts Price Target to $1 From $5 MT
Bruker to Acquire PhenomeX in $108 Million All-Cash Deal MT
Bruker Corp & Phenomex Inc Announce Agreement For Bruker To Acquire Phenomex In All-Cash Transaction RE
Bruker Corporation signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc.. CI
Berenberg Bank Adjusts PhenomeX Price Target to $8 From $9, Maintains Buy Rating MT
Earnings Flash (CELL) PHENOMEX Posts Q2 Revenue $14.1M, vs. Street Est of $17.4M MT
Earnings Flash (CELL) PHENOMEX Posts Q2 Revenue $14.1M, vs. Street Est of $17.4M MT
PhenomeX Inc. Announces Impairment of Goodwill for the Second Quarter Ended June 30, 2023 CI
PhenomeX Inc. Reiterates Earning Guidance for the Full Year of 2023 CI
PhenomeX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Phenomex Board Launches A Process to Explore, Review, Evaluate A Range of Potential Strategic Alternatives CI
Chart Bruker Cellular Analysis, Inc.
More charts
PhenomeX Inc., formerly Berkeley Lights, Inc., is a functional cell biology company. The Company enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The Company enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company's platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.
More about the company
  1. Stock
  2. Equities
  3. Stock Bruker Cellular Analysis, Inc. - Nyse
  4. News Bruker Cellular Analysis, Inc.
  5. Berkeley Lights : Berenberg Bank Initiates Coverage on Berkeley Lights With Buy Rating, $42 Price Target